A Randomized, Open Label Parallel Group Mechanical Prophylaxis Controlled Comparison Study With YM150, a Direct Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery.
Phase of Trial: Phase III
Latest Information Update: 01 Sep 2012
At a glance
- Drugs Darexaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 01 Sep 2012 Results published in Thrombosis Research.
- 15 Jun 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 15 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.